1. Home
  2. Analysis
  3. Short-term-memory-loss

Short-term memory loss: treatments, associated drugs and conditions

Summary:

We study 244,445 people who have Short-term memory loss. The information that eHealthMe analyzes includes:

- Medications that treat Short-term memory loss and their effectiveness
- 3,590 drugs that are associated with Short-term memory loss


eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

Number of reports submitted per year:

Short-term memory loss: 244,445 reports.

Short-term memory loss treatments and how effective are they?

All the drugs that are associated with Short-term memory loss:

Do you take any medication?

- You can use our AI-powered tools to monitor drug safety and effectiveness.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

How we gather our data?

Healthcare data is obtained from a number of sources including the Food and Drug Administration (FDA). This information is aggregated and used to produce personalized reports that patients can reference. Browse all conditions on eHealthMe.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.